Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, NMI Developing Assays for Autoimmune Diseases, Cancer

NEW YORK (GenomeWeb News) – Protagen and the Natural and Medical Sciences Institute at the University of Tubingen announced they will be developing multiplex assays for the diagnosis of autoimmune diseases and cancer.

The deal will leverage Protagen's expertise in the high-throughput expression of human proteins and clinical validation studies, and the institute's research platform.

"For several years our focus has been on development of testing systems using planar and bead-based protein microarrays," Hugo Hämmerle, a professor at NMI, said in a statement. "The competence and capability of our research platform was already validated by a number of projects with international partners from industry and academia. The cooperation with Protagen allows us to collaborate on the commercialization of assays for personalized medicine."

Financial and other terms of the deal were not disclosed.

Protagen is based in Dortmund, Germany and specializes in in vitro diagnostics. The company has two business units, Diagnostics and Protein Services. NIMI also based in Germany is an application-focused research institute that makes research results available to industry.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.